Close Menu

NEW YORK – Roche on Thursday reported a 3 percent decline in half-year revenues for its Diagnostics division. At constant exchange rates, however, diagnostics revenues were up 3 percent, and the main driver of both revenue gains and misses was the COVID-19 pandemic.

For the first half of 2020, the Roche Group reported CHF 29.28 billion ($31.53 billion) in total sales, down 4 percent (up 1 percent at constant exchange rates) from CHF 30.47 billion during the first half of 2019.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.